While short-term LC supplementation has demonstrated positive effects, including increased endurance, improved hepatic fat metabolism, and myocardial stability, evidence indicates that the prolonged supplementation may pose risks, particularly for individuals with pre-existing cardiovascular or renal conditions
None of its four components, GHK-Cu, BPC-157, TB-500, or KPV, have completed clinical trials for any approved indication
10 Limitations: Do not use in cancer or tumor
Increased incidence and altered risk demographics of childhood lead poisoning: predicting the impacts of the CDCs 5 g/dL reference value in Massachusetts (USA)
doi: 10.1038/srep09245 17 CohanimA
Claims involving fat loss, obesity, glucose control, liver disease, sarcopenia, metabolism or anti-ageing could contribute to medicinal classification